Japanese-based pharmaceutical firm Takeda Pharmaceutical has concluded enrolment in Phase III tetravalent immunisation against dengue efficacy study (TIDES) trial of TAK-003 to protect against all four strains of the dengue virus.

TAK-003 is the firm's live-attenuated tetravalent dengue vaccine candidate.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The double-blind, randomised and placebo-controlled Phase III trial enrolled 20,100 children and adolescents aged four to 16.

The trial will assess the efficacy, safety and immunogenicity in eight dengue-endemic countries in Latin America and Asia, including Brazil, Colombia, Panama, Dominican Republic, Nicaragua, Philippines, Thailand and Sri Lanka.

Takeda Global Vaccine business unit president Rajeev Venkayya said: “The successful enrolment of more than 20,000 children and adolescents in this Phase III trial, across several continents, and on an ambitious timeline, while maintaining a clear focus on quality and subject safety, reflects Takeda’s prioritisation of dengue and the substantial capabilities of our global organisation."

See Also:

"The TIDES trial will evaluate two subcutaneous doses of TAK-003, given three months apart at Day 1 and Day 90."

The TIDES trial will evaluate two subcutaneous doses of TAK-003, given three months apart at Day 1 and Day 90.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's primary objective is protection against virologically confirmed dengue of any severity and by any of the dengue serotypes.

The secondary endpoints will measure the efficacy of the vaccine to prevent the disease, hospitalisation and severe dengue associated with any dengue serotype.

The frequency and severity of adverse events (AEs) or serious AEs, seropositivity rate and geometric mean titers (GMTs) of neutralising antibodies in the immunogenicity subset will also be examined.

The initial results of the Phase III TIDES trial are expected to be reported next year.